graft versus host disease


Also found in: Dictionary, Acronyms, Wikipedia.

graft ver·sus host dis·ease (GVHD),

an incompatibility reaction (that may be fatal) in a subject (host) of low immunologic competence who has been the recipient of immunologically competent lymphoid tissue from a donor who is immunologically different from the recipient; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess an antigen not found in the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 7-30 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Synonym(s): GVH disease

Graft versus host disease

A life-threatening complication of bone marrow transplants in which the donated marrow causes an immune reaction against the recipient's body.
References in periodicals archive ?
According to Niche Markets and Rare Diseases: Graft Versus Host Disease, expert physicians report that Velcade's market potential could be even greater, based on their interest in employing Velcade in the prophylactic setting.
About Graft Versus Host Disease Graft Versus Host Disease is offered as part of Decision Resources' Niche Markets and Rare Diseases service.
Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism.
Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD).
Moreover, clinicians have reported positive results using ATG-FRESENIUS S for conditioning regimens and prevention of graft versus host disease in bone marrow transplantation.
His extensive licensing experience will be essential in building value in our biotherapeutic programs as we are eagerly awaiting the results of our pivotal Phase III clinical trial of orBec(R) in intestinal graft versus host disease.
Enzo said that EGS21, together with the Company's current oral immune regulation platform, could accelerate the Company's development and launching of products for treatment of a broad range of immune mediated diseases including hepatitis B virus (HBV) and hepatitis C virus (HCV) associated liver disease, various cancers, Crohn's disease and other forms of inflammatory bowel diseases, HIV, diabetes and graft versus host disease.
Enzo believes that the continued exploitation of these three powerful and significant immune regulation platforms will enable the Company to develop and launch products for treatment of a broad range of immune mediated diseases including hepatitis B virus and hepatitis C virus (HCV) associated liver disease, various cancers, Crohn's disease and other forms of inflammatory bowel diseases, diabetes and graft versus host disease.
Using irradiated blood in transfusions is recognized as the most effective way of preventing Transfer Associated Graft Versus Host Disease (TA-GVHD).